Palbociclib

As a federal NDC-monographed kinase inhibitor (0069-0486, 63539-284, manufactured/labeled by Pfizer Laboratories Div Pfizer Inc), Palbociclib provides oral-route dosing across 100 mg/1 Tablet, Film Coated and 75 mg/1 Tablet, Film Coated under licensed medical supervision.

Acting as a oral-route kinase inhibitor moiety, Palbociclib (NDC 0069-0486, 63539-284, manufactured/labeled by Pfizer Laboratories Div Pfizer Inc) regulates downstream signaling pathways proportional to 100 mg/1 Tablet, Film Coated and 75 mg/1 Tablet, Film Coated titration and patient renal/hepatic reserve.

Clinical clearance of Palbociclib (Kinase Inhibitor) relies on predominantly hepatic biotransformation with renal elimination of polar palbociclib conjugates with a Steady-state plasma equilibrium reached over 9–20 hour t½ intervals for Palbociclib half-life; patients absorbing at Approximately 79% to 91% enteral uptake across labeled Palbociclib strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–5 hours after palbociclib dosing.

FDA clinical labeling for Palbociclib restricts administration in previous anaphylactoid or exfoliative reaction attributed to palbociclib; clinical scenarios where kinase inhibitor exposure from palbociclib poses unacceptable risk across 100 mg/1 Tablet, Film Coated, 75 mg/1 Tablet, Film Coated, 75 mg/1 Capsule, 125 mg/1 Tablet, Film Coated, 100 mg/1 Capsule, with self-reported patient tracking dominated by headache (7.6% of reports), nausea (7.4% of reports), dizziness (6.4% of reports).